Acute Abdomen from Kayexalate UtilizationMehulkumar Joshi*, Tu Tran Hyunh, Shotaro Sano and Jaime TE
Department of Surgery, St. John’s Episcopal Hospital, USA
- Corresponding Author:
- Mehulkumar Joshi
Department of Surgery, St. John’s
Episcopal Hospital, USA
Tel: +1 718-869-8822
E-mail: [email protected]
Received date: October 12, 2016; Accepted date: November 24, 2016; Published date: November 30, 2016
Citation: Joshi M, Hyunh TT, Sano S, Jaime TE (2016) Acute Abdomen from Kayexalate Utilization. J Clin Case Rep 6:889. doi: 10.4172/2165-7920.1000889
Copyright: © 2016 Joshi M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hyperkalemia in end stage renal disease patients is a common complication. Sodium polystyrene sulfonate (Kayexalate) is a commonly used in the treatment of hyperkalemia. This case report discusses about Kayexalateinduced colonic necrosis, a rare but fatal complication of this commonly used medication.
Sodium polystyrene sulfonate; Kayexalate; Bowel; Necrosis; Acute abdomen
Sodium polystyrene sulfonate (SPS, Kayexalate), has been used in management of hyperkalemia since 1957 when it was first discovered. Kayexalate is a cation resin used either as oral or as an enema form in the management of hyperkalemia. Originally sorbitol was mixed with sodium polystyrene sulfonate as a cathartic to avoid constipation. Even though kayexalate is used often to treat hyperkalemia, its side effect of colonic necrosis is a rare complication that was first discussed in 1987, in a series featuring five uremic patients. The study led to the FDA advisory to discontinue the addition of sorbitol due to this associated risk of colonic necrosis .